664 research outputs found
Tebbutt, W J (William John), QX10559
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/420807Surname: TEBBUTT. Given Name(s) or Initials: W J (WILLIAM JOHN). Military Service Number or Last Known Location: QX10559. Missing, Wounded and Prisoner of War Enquiry Card Index Number: 32205.245517
Item: [2016.0049.53068] "Tebbutt, W J (William John), QX10559
Tebbutt, Henry J, [No Service Number]
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/420805Surname: TEBBUTT. Given Name(s) or Initials: HENRY J. Military Service Number or Last Known Location: [No Registration Number]. Missing, Wounded and Prisoner of War Enquiry Card Index Number: 17544.245515
Item: [2016.0049.53066] "Tebbutt, Henry J, [No Service Number]
J. Tebbutt. — Rapport sur les travaux de l’observatoire de M. J. Tebbutt, à Windsor, Nouvelle-Galles du Sud, pour l’année 1892
No full textJ. Tebbutt. — Rapport sur les travaux de l’observatoire de M. J. Tebbutt, à Windsor, Nouvelle-Galles du Sud, pour l’année 1892. In: Bulletin astronomique, tome 10, 1893. pp. 433-436
Riem (J.)· — Ueber eine frühere Erscheinung des Kometen 1881 III Tebbutt. Gœttingue, 1896
No full textRiem (J.)· — Ueber eine frühere Erscheinung des Kometen 1881 III Tebbutt. Gœttingue, 1896. In: Bulletin astronomique, tome 13, 1896. p. 460
Less surgery, improved survival from stage IV colorectal cancer?
No full textLetter to the EditorTimothy J. Price, Niall Tebbutt, Amanda R. Townsen
Fc-gamma receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer
No full textAbstract not availableGeoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A. Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy J. Price, Niall C. Tebbutt, Jeremy D. Shapiro, G. Mark Jeffery, J. Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois E. Shepherd, Derek J. Jonker, Christopher J. O'Callaghan, John R. Zalcberg, Christos S. Karapetis, and Alexander Dobrovi
The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
No full textPURPOSE: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. METHODS: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. RESULTS: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82-0.91, P<0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67-0.74, P<0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03-2.78, P<0.00001). Grade 3/4 toxicity was increased with OR 2.34. Considering by subgroups, EGFR inhibitors (EGFR-I) in the second-line setting and anti-angiogenic therapies (both in second-line and third-line and beyond settings) all improved overall survival, PFS and ORR. EGFR-I in third-line settings improved PFS and ORR but not OS. CONCLUSIONS: The use of biologic agents in mCRC after first-line treatment is associated with improved outcomes but increased toxicity.E Segelov, D Chan, J Shapiro, T J Price, C S Karapetis, N C Tebbutt and N Pavlaki
The effect of low and high-intensity cycling in diesel exhaust on flow-mediated dilation, circulating NOx, endothelin-1 and blood pressure
No full textINTRODUCTION:
Exposure to air pollution impairs aspects of endothelial function such as flow-mediated dilation (FMD). Outdoor exercisers are frequently exposed to air pollution, but how exercising in air pollution affects endothelial function and how these effects are modified by exercise intensity are poorly understood.
OBJECTIVES:
Therefore, the purpose of this study was to determine the effects of low-intensity and high-intensity cycling with diesel exhaust (DE) exposure on FMD, blood pressure, plasma nitrite and nitrate (NOx) and endothelin-1.
METHODS:
Eighteen males performed 30-minute trials of low or high-intensity cycling (30% and 60% of power at VO2peak) or a resting control condition. For each subject, each trial was performed once while breathing filtered air (FA) and once while breathing DE (300ug/m3 of PM2.5, six trials in total). Preceding exposure, immediately post-exposure, 1 hour and 2 hours post-exposure, FMD, blood pressure and plasma endothelin-1 and NOx concentrations were measured. Data were analyzed using repeated-measures ANOVA and linear mixed model.
RESULTS:
Following exercise in DE, plasma NOx significantly increased and was significantly greater than FA (p<0.05). Two hours following DE exposure, endothelin-1 was significantly less than FA (p = 0.037) but exercise intensity did not modify this response. DE exposure did not affect FMD or blood pressure.
CONCLUSION:
Our results suggest that exercising in DE did not adversely affect plasma NOX, endothelin-1, FMD and blood pressure. Therefore, recommendations for healthy individuals to moderate or avoid exercise during bouts of high pollution appear to have no acute protective effect.Peer reviewedFinal article published
Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors
No full textDuring the last 20 years there have been major therapeutic developments in colorectal cancer (CRC) with the introduction of multiple novel therapeutic agents into routine clinical practice. This has improved survival in both the adjuvant and advanced disease settings. However, improvements have come with substantial increases in expense to the community and potential toxicity to the patient. There has been substantial research to identify tumour factors in CRC that predict treatment response and survival outcomes. This research has identified clinically useful predictive biomarkers to aid clinical decision making, such as the presence or absence of KRAS gene mutations which can determine the benefit of using epidermal growth factor receptor (EGFR) inhibiting antibodies. However, less attention has been paid to the identification and impact of predictive patient-derived factors such as age, gender and the presence of comorbid conditions or evidence of a systemic inflammatory response. In this article, the current concepts of tumour and patient-related predictive factors in CRC management are reviewed.Stephen J. Clarke, Christos S. Karapetis, Peter Gibbs, Nick Pavlakis, Jayesh Desai, Michael Michael, Niall C. Tebbutt, Tim J. Price and Josep Taberner
- …
